Radiation and Hormone Therapy for Prostate Cancer

(DIVINE Trial)

Recruiting at 1 trial location

Overseen By Clinical Trials Referral Office

Age: 18+

Sex: Male

Trial Phase: Phase 2

Sponsor: Mayo Clinic

Must be taking: Androgen deprivation

Must not be taking: Chemotherapy, Androgen inhibitors

Disqualifiers: Pregnancy, Active infection, Heart failure, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 6

Duration: 6 months

220 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how different treatment combinations can manage hormone-sensitive prostate cancer that has spread and returned after improvement. It compares two approaches: using precise radiation therapy (Stereotactic Body Radiation Therapy, or SBRT) with or without additional hormone treatments that block androgen, the male hormone that can fuel cancer growth. Participants with prostate cancer that has spread to five or fewer locations outside the pelvis and have not received certain therapies before may be suitable for this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer treatment.

Do I need to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you have been on androgen receptor pathway inhibitors in the last 2 years, you may not be eligible to participate.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that Stereotactic Body Radiation Therapy (SBRT) is generally safe and well-tolerated. It effectively targets tumors while sparing normal tissue. In one study, only 2.25% of patients experienced serious side effects.

For treatments involving androgen receptor pathway inhibitors (ARPI) and androgen deprivation therapy (ADT), the safety data is also reassuring. Abiraterone, an ARPI, does not increase the risk of severe side effects compared to standard treatments. Most patients experienced some side effects, but these were not more severe than with other treatments.

Goserelin, used in ADT, commonly and effectively lowers testosterone levels. Typical side effects include hot flashes and some pain, which are expected with this type of treatment.

Overall, these treatments are well-researched and generally safe, with common side effects that most patients can manage. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for prostate cancer because they combine advanced radiation therapy with hormone therapy in innovative ways. Stereotactic Body Radiation Therapy (SBRT) is unique because it delivers high doses of radiation precisely to the tumor in fewer sessions, potentially reducing treatment time and side effects compared to traditional radiation therapy. In Group A, SBRT is paired with a combination of hormone-blocking drugs (like APRI and ADT), which may enhance the effectiveness of the radiation by disrupting cancer growth pathways. Group B emphasizes a less aggressive approach by combining SBRT with watchful waiting, which could be beneficial for patients who prefer to avoid the side effects of hormone therapy. This trial aims to explore how these strategies can be optimized for better outcomes and fewer side effects.

What evidence suggests that this trial's treatments could be effective for prostate cancer?

Research has shown that stereotactic body radiation therapy (SBRT) can be very effective for prostate cancer. SBRT has successfully controlled the disease over the long term, especially in cases with low to intermediate risk. In this trial, participants in Group B will undergo SBRT with watchful waiting.

Participants in Group A will receive another treatment option, which combines SBRT with APRI (abiraterone and prednisone, apalutamide, darolutamide, or enzalutamide) and ADT (leuprolide, triptorelin, histrelin, goserelin, degarelix, or relugolix). Research has shown that abiraterone, when used with prednisone, helps patients with advanced prostate cancer live longer and slows the disease. Additionally, goserelin, a type of hormone therapy, lowers testosterone levels, which can help slow cancer growth. Combining SBRT with treatments like abiraterone and goserelin may improve effectiveness by attacking the cancer in different ways. ^{6 7 8 9 10}

Who Is on the Research Team?

Jacob Orme

Principal Investigator

Mayo Clinic in Rochester

Are You a Good Fit for This Trial?

This trial is for men with hormone-sensitive prostate cancer that has spread and returned after improving. Participants should not have allergies to the treatments used in the study, which include various medications and radiation therapy.

Inclusion Criteria

Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x upper limit of normal (ULN) ( ≤ 5 x ULN for patients with liver involvement) (obtained ≤ 15 days prior to registration)

I have up to 5 cancer spread sites, with at least one outside my pelvis.

Willingness to provide mandatory blood specimens for correlative research

Exclusion Criteria

I have received chemotherapy for prostate cancer.

I had surgery less than 3 weeks ago.

Pregnant persons

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo SBRT and receive ARPI and ADT for up to 6 months, with cycles repeating every 4 months

6 months

Regular visits for treatment and monitoring

Watchful Waiting

Patients are monitored for disease progression after treatment

Until disease progression

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 5 years

Follow-up every 6 months

What Are the Treatments Tested in This Trial?

Interventions

• Abiraterone
• Goserelin
• Stereotactic Body Radiation Therapy

Trial Overview The DIVINE Trial is testing how well stereotactic body radiation therapy (SBRT) works alone or when combined with ARPIs and ADT in treating metastatic, recurrent prostate cancer. It compares different treatment timings to see which is more effective.

How Is the Trial Designed?

Group I: Group B (SBRT, watchful waiting) Experimental Treatment 8 Interventions

Patients undergo SBRT with watchful waiting. Cycles repeat every 4 months (16 weeks) in the absence of disease progression or unacceptable toxicity.

Group II: Group A (SBRT, APRI, ADT) Active Control 19 Interventions

Patients undergo SBRT and receive APRI (abiraterone and prednisone, apalutamide, darolutamide, or enzalutamide) and ADT (leuprolide, triptorelin, histrelin, goserelin, degarelix, or relugolix). Cycles repeat every 4 months (16 weeks) for up to 6 months in the absence of unacceptable toxicity. Patients then undergo watchful waiting thereafter until disease progression.

Stereotactic Body Radiation Therapy is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Stereotactic Body Radiation Therapy for:

• Non-small cell lung cancer (NSCLC)
• Melanoma
• Renal cell carcinoma (RCC)
• Prostate cancer
• Oligoprogressive cancers

Approved in European Union as Stereotactic Body Radiation Therapy for:

• Non-small cell lung cancer (NSCLC)
• Melanoma
• Renal cell carcinoma (RCC)
• Prostate cancer
• Oligoprogressive cancers

Approved in Canada as Stereotactic Body Radiation Therapy for:

• Non-small cell lung cancer (NSCLC)
• Melanoma
• Renal cell carcinoma (RCC)
• Prostate cancer
• Oligoprogressive cancers

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

CyberKnife stereotactic ablative radiotherapy (SABR) for treating intermediate- to very-high-risk prostate cancer showed a high 3-year biochemical relapse-free survival rate of 90.2%, indicating its efficacy in managing this condition.

The treatment was well-tolerated, with no patients experiencing severe toxicity (≥ grade 3), and only mild genitourinary and gastrointestinal side effects were reported, suggesting a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results. Fan, CY., Chao, HL., Huang, WY., et al.[2017]

In a study of 87 men with oligometastatic prostate cancer treated with stereotactic ablative radiotherapy (SABR), the median disease-free survival (DMFS) was 21.8 months for hormone-sensitive patients, indicating a significant benefit from this treatment.

Combining SABR with short-term androgen-deprivation therapy improved both biochemical progression-free survival (bPFS) and DMFS in patients with oligorecurrent hormone-sensitive prostate cancer, suggesting a potential strategy for enhancing treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer. Mercier, C., Claessens, M., De Troyer, B., et al.[2022]

In a study of 84 low-risk prostate cancer patients treated with Stereotactic Ablative Body Radiotherapy (SABR), long-term quality of life (QOL) outcomes were generally positive, with a median follow-up of 50.8 months, although some patients reported declines in urinary (17.9%), bowel (26.2%), and sexual (37.5%) QOL domains.

Dosimetric factors such as rectal D1cc and penile bulb V35 were identified as significant predictors of worse QOL, highlighting the importance of adhering to strict dosimetric constraints to minimize side effects from treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Elias, E., Helou, J., Zhang, L., et al.[2018]

In a study of 26 men with low- to intermediate-risk prostate cancer treated with CyberKnife SBRT, there was a significant reduction in PSA levels, indicating an effective biochemical response to the therapy.

Despite a decrease in testosterone levels post-treatment, there was no increase in biochemical hypogonadism one year after therapy, suggesting that CyberKnife SBRT is well-tolerated and does not significantly impact hormonal health.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. Oermann, EK., Suy, S., Hanscom, HN., et al.[2022]

In a study comparing two different fractionation schedules of stereotactic ablative radiotherapy (SABR) for prostate cancer, the 2-fraction treatment (26 Gy/2) showed significantly better quality of life (QOL) outcomes in the bowel domain compared to the 5-fraction treatment (40 Gy/5), with a lower rate of clinically important changes in bowel function.

Both treatment groups had low five-year biochemical failure rates (3.3% for 2-fraction and 4.6% for 5-fraction), indicating that the 2-fraction SABR is not only effective but also well tolerated, warranting further randomized trials to confirm these findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. Alayed, Y., Quon, H., Cheung, P., et al.[2020]

Stereotactic ablative radiotherapy (SABR) using Cyberknife demonstrated high effectiveness in treating stage I non-small-cell lung cancer, with 2-year local control, progression-free, and overall survival rates of 91.9%, 61.7%, and 84.8%, respectively, based on a study of 153 patients.

The treatment was generally safe, with only 8.1% of patients experiencing severe toxicities, including one case of grade 5 radiation pneumonitis, indicating that while SABR is effective, careful monitoring for side effects is necessary.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis. Hayashi, K., Suzuki, O., Shiomi, H., et al.[2022]

Stereotactic ablative radiotherapy (SABR) is a safe and effective treatment for low and intermediate risk prostate cancer, with only a 2.25% failure rate observed in a study of 400 patients over a median follow-up of 15 months.

The treatment resulted in a significant decline in prostate-specific antigen (PSA) levels, with no severe late adverse effects reported, indicating that SABR could be considered for more advanced cases of prostate cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients Miszczyk, L., Namysł Kaletka, A., Napieralska, A., et al.[2020]

Stereotactic body radiation therapy (SBRT) using CyberKnife for localized prostate cancer was found to be safe, with no severe treatment-related toxicities (grade 3 or higher) reported among 44 patients over a median follow-up of 40 months.

The treatment showed excellent efficacy, with a 100% cause-specific survival rate and progression-free survival rate, and a high biochemical failure-free rate of 90.8% for high-risk patients, particularly with the 34 Gy in 4 fractions regimen.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Image-guided stereotactic body radiation therapy for localized prostate cancer. Kang, JK., Cho, CK., Choi, CW., et al.[2022]

A single session of stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer was found to be feasible and safe, with only one significant adverse event (a vertebral fracture) reported among 33 patients over a 2-year follow-up period.

The treatment resulted in high local progression-free survival rates of 97% at 1 year and 93% at 2 years, with nearly half of the patients (48%) avoiding the need for androgen deprivation therapy at the 2-year mark, indicating effective disease control and maintained quality of life.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Siva, S., Bressel, M., Murphy, DG., et al.[2022]

Stereotactic ablative radiation (SAbR) at a dose of 45 Gy in 5 fractions shows a promising safety profile for treating localized prostate cancer, with acute urinary and gastrointestinal toxicity rates of 20.4% and 7.3%, respectively, and low rates of late toxicity after 2 years.

The treatment demonstrated excellent efficacy, with a biochemical failure-free survival rate of 100% at 1 year and 98.7% at 2 years, indicating strong disease control outcomes for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Chen, L., Gannavarapu, BS., Desai, NB., et al.[2022]

Citations

1. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/40531349/

The efficacy of abiraterone in metastatic hormone-sensitive ... Results: Data for 3374 patients were analyzed. In the overall population, abiraterone improved OS (HR: 0.66, 95% CI 0.59-0.73) and PFS (HR: 0.51, 95% CI ...

2. ecancer.org ecancer.org/en/news/26791-lower-dose-of-abiraterone-acetate-as-effective-for-prostate-cancer-treatment

Lower dose of abiraterone acetate as effective for prostate ... In their study involving nine men with metastatic prostate cancer, they found that this lower dose resulted in comparable cancer suppression.

3. jamanetwork.com jamanetwork.com/journals/jamanetworkopen/fullarticle/2840898

Abiraterone vs Enzalutamide for Metastatic Hormone ... This cohort study evaluates clinical outcomes in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone acetate ...

4. urologytimes.com urologytimes.com/view/lower-dose-of-abiraterone-shows-comparable-efficacy-to-standard-dose-for-prostate-cancer

Lower dose of abiraterone shows comparable efficacy to ... A 500 mg dose of abiraterone acetate showed comparable efficacy to the standard 1000 mg dose in prostate cancer treatment, with a favorable ...

5. nejm.org nejm.org/doi/full/10.1056/NEJMoa1704174

Abiraterone plus Prednisone in Metastatic, Castration- ... The median length of radiographic progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group ( ...

6. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/40940844/

The Safety of Abiraterone Acetate in Patients with Metastatic ... Nearly all participants experienced at least one adverse event (98.4% abiraterone, 97.3% standard of care [SOC]).

7. mdpi.com mdpi.com/2072-6694/17/17/2747

The Safety of Abiraterone Acetate in Patients with ... Conclusions: In this IPD meta-analysis, abiraterone acetate provides no greater risk of SAE in those receiving abiraterone than those receiving SOCs. Patients ...

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC8105236/

Real-World Safety and Efficacy Outcomes with Abiraterone ... Abiraterone acetate plus prednisone or prednisolone (AAP) prolongs survival in chemotherapy-naive and docetaxel-experienced patients.

9. e-juo.org e-juo.org/journal/view.php?number=594

Assessing Patient Risk, Benefit, and Outcomes in Drug ... Nearly all clinical trials testing abiraterone in prostate cancer showed promising outcomes with 89% of studies meeting their endpoint.

10. yonsarx.com yonsarx.com/efficacy-and-safety

Efficacy and Safety | YONSA® (abiraterone acetate) Hepatotoxicity: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue YONSA® dosing as recommended. In post-marketing experience ...